Alvotech Feed

2025-07-04 01:02:28 Notification for the purposes of article 13 of the Luxembourg law of 11 January 2008 on transparency requirements for issuers

2025-07-02 01:54:39 Úthlutun nýrra kauprétta og afhending áunninna hlutabréfaréttinda

2025-07-02 01:54:39 Granting of Stock Options and Vesting of Restricted Share Units

2025-07-01 10:00:00 Alvotech and Advanz Pharma ingår europeiskt leverans- och kommersialiseringsavtal för biosimilarkandidat till Cimzia® (certolizumab pegol) 1115,00 ISK | +0,45% | 53,4 MISK

2025-07-01 10:00:00 Advanz Pharma semur við Alvotech um markaðssetningu í Evrópu á hliðstæðu við líftæknilyfið Cimzia 1115,00 ISK | +0,45% | 53,4 MISK

2025-07-01 10:00:00 Alvotech and Advanz Pharma Enter into European Supply and Commercialization Agreement for Biosimilar Candidate to Cimzia® (certolizumab pegol) 1115,00 ISK | +0,45% | 53,4 MISK

2025-06-26 10:15:00 Alvotech’s Lenders Lower Interest on Senior Secured Term Loan Facility 1135,00 ISK | +0,89% | 76,5 MISK

2025-06-26 10:15:00 Alvotechs långivare sänker räntan på senior säkerställd lånefacilitet 1135,00 ISK | +0,89% | 76,5 MISK

2025-06-26 10:15:00 Lánveitendur Alvotech lækka vexti á langtímaskuldum félagsins 1135,00 ISK | +0,89% | 76,5 MISK

2025-06-26 10:15:00 Alvotech’s Lenders Lower Interest on Senior Secured Term Loan Facility 1135,00 ISK | +0,89% | 76,5 MISK

2025-06-25 22:45:00 Niðurstaða aðalfundar Alvotech árið 2025 1135,00 ISK | +0,89% | 76,5 MISK

2025-06-25 22:45:00 Main Results of 2025 Annual and Extraordinary General Meeting 1135,00 ISK | +0,89% | 76,5 MISK

2025-06-25 10:00:00 Positive Top Line Results from Confirmatory Efficacy Study for Proposed Biosimilar to Xolair® (omalizumab) 1125,00 ISK | 0,00% | 43,5 MISK

2025-06-25 10:00:00 Jákvæð niðurstaða úr klínískri rannsókn fyrir fyrirhugaða hliðstæðu Alvotech við líftæknilyfið Xolair 1125,00 ISK | 0,00% | 43,5 MISK

2025-06-25 10:00:00 Positive Top Line Results from Confirmatory Efficacy Study for Proposed Biosimilar to Xolair® (omalizumab) 1125,00 ISK | 0,00% | 43,5 MISK

2025-06-23 10:00:00 Lyfjastofnun Evrópu mælir með því að veita markaðsleyfi fyrir AVT06, fyrirhugaða hliðstæðu Alvotech við augnlyfið Eylea 176 MISK

2025-06-23 10:00:00 European Medicines Agency Recommends Market Approval of AVT06, Alvotech’s Proposed Biosimilar to Eylea® (aflibercept) 176 MISK

2025-06-11 22:20:10 Öll bréf afhent kaupendum í hlutafjárútboði Alvotech 1235,00 ISK | -0,40% | 134 MISK

2025-06-11 22:20:10 Alvotech’s Private Placement Completed with Delivery of SDRs and Shares to Investors 1235,00 ISK | -0,40% | 134 MISK

2025-06-11 22:18:08 Alvotech’s Private Placement Completed with Delivery of SDRs and Shares to Investors 1235,00 ISK | -0,40% | 134 MISK

2025-06-06 14:30:00 Alvotech Meets Investors and Presents at the Goldman Sachs Global Healthcare Conference in Miami 1360,00 ISK | +0,74%

2025-06-06 14:30:00 Alvotech tekur þátt í árlegri heilbrigðisráðstefnu Goldman Sachs fjárfestingabankans í Miami 1360,00 ISK | +0,74%

2025-06-06 14:30:00 Alvotech Participates in the Goldman Sachs Global Healthcare Conference in Miami 1360,00 ISK | +0,74%

2025-06-05 08:55:00 Alvotech and Dr. Reddy’s Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab) 1350,00 ISK | -6,25% | 8 340 MISK

2025-06-05 08:55:00 Alvotech og Dr. Reddys ganga til samstarfs um þróun hliðstæðu við krabbameinslyfið Keytruda 1350,00 ISK | -6,25% | 8 340 MISK

2025-06-05 08:55:00 Alvotech and Dr. Reddy’s Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab) 1350,00 ISK | -6,25% | 8 340 MISK

2025-06-05 04:29:32 Alvotech has carried out a private placement of 7,500,000 SDRs and ordinary shares at a price of SEK 100.00 per SDR and ISK 1320.83 per ordinary share, raising gross proceeds of SEK 750 million 1350,00 ISK | -6,25% | 8 340 MISK

2025-06-05 01:55:00 Alvotech lýkur lokuðu útboði á alls 7.500.000 sænskum heimildarskírteinum (SDR) og hlutabréfum á genginu 100 sænskar krónur fyrir hvert SDR og 1.320,83 íslenskar krónur fyrir hvern hlut, að heildarfjárhæð 750 milljónir sænskra króna 1350,00 ISK | -6,25% | 8 340 MISK

2025-06-05 01:55:00 Alvotech has carried out a private placement of 7,500,000 SDRs and ordinary shares at a price of SEK 100.00 per SDR and ISK 1320.83 per ordinary share, raising gross proceeds of SEK 750 million 1350,00 ISK | -6,25% | 8 340 MISK

2025-06-04 17:32:42 Alvotech ráðgerir útboð til stofnanafjárfesta á um 7,5 milljónum sænskra heimildarskírteina og hlutabréfum 1350,00 ISK | -6,25% | 8 340 MISK

2025-06-04 17:32:42 Alvotech intends to carry out a private placement of approximately 7.5 million SDRs and ordinary shares 1350,00 ISK | -6,25% | 8 340 MISK

2025-06-04 13:45:00 Alvotech lýkur við kaup á rannsóknaraðstöðu Xbrane og fyrirhugaðri hliðstæðu við Cimzia 1440,00 ISK | 0,00% | 8,76 MISK

2025-06-04 13:45:00 Alvotech Completes Acquisition of Xbrane R&D Organization and biosimilar candidate to Cimzia® 1440,00 ISK | 0,00% | 8,76 MISK

2025-06-02 15:15:00 Alvotech Meets Investors and Presents at the Jefferies Global Healthcare Conference 2025 in New York, NY 1445,00 ISK | -0,34%

2025-06-02 15:15:00 Alvotech fundar með fjárfestum á árlegri heilbrigðisráðstefnu Jefferies fjárfestingabankans í New York og flytur kynningu 1445,00 ISK | -0,34%

2025-06-02 15:15:00 Alvotech Meets Investors and Presents at the Jefferies Global Healthcare Conference 2025 in New York, NY 1445,00 ISK | -0,34%

2025-05-28 12:15:00 Alvotech and Advanz Pharma Extend Strategic Partnership to Commercialize Three Additional Biosimilars in Europe 1445,00 ISK | +3,58%

2025-05-28 12:15:00 Advanz Pharma semur við Alvotech um rétt til markaðssetningar þriggja fyrirhugaðra hliðstæða til viðbótar í Evrópu 1445,00 ISK | +3,58%

2025-05-28 12:15:00 Alvotech and Advanz Pharma Extend Strategic Partnership to Commercialize Three Additional Biosimilars in Europe 1445,00 ISK | +3,58%

2025-05-26 20:06:57 Aðalfundur Alvotech boðaður 25. júní 2025 1395,00 ISK | +2,20%

2025-05-26 20:06:57 Alvotech Annual General Meeting to be held June 25, 2025 1395,00 ISK | +2,20%

2025-05-23 18:11:25 Viðskipti stjórnenda og tengdra aðila 1275,00 ISK | -1,16%

2025-05-23 18:11:25 Transactions of Managers and Closely Associated Persons 1275,00 ISK | -1,16%

2025-05-19 09:15:00 Alvotech semur við fjárfestingabankann DNB Carnegie um viðskiptavakt á Nasdaq markaðnum í Stokkhólmi 1330,00 ISK | -1,48%

2025-05-19 09:15:00 Alvotech Appoints DNB Carnegie as Liquidity Provider on Nasdaq Stockholm 1330,00 ISK | -1,48%

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Alvotech

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden